Three different things: an intervention may be approved for a specific indication, under evaluation in a clinical trial, or only a longer-term scientific possibility. NeuroCoach keeps those categories separate so new findings can be interesting without becoming misleading medical advice.
Featured FDA research workshop · November 10, 2026
Transcranial focused ultrasound is an emerging research approach, including experimental psychiatric neuromodulation. FDA and the Focused Ultrasound Foundation are holding a free public meeting on evidence, device safety and clinical-trial standards. The workshop is not a new medical-device approval.
Official sources we monitor
TRIAL REGISTRY
ClinicalTrials.gov
New or updated study registrations, recruiting status, age requirements and study design. A registered study is not proof that a treatment works.
Open official source ↗RESEARCH INDEX
PubMed
Research citations including trials and reviews. We link to the original paper so readers can check methods, study size, endpoints and limitations.
Open official source ↗REGULATORY SOURCE
FDA
Medication and medical-device notices. An FDA research announcement is not the same as an approval for a particular diagnosis.
Open official source ↗Important: Imported entries are marked as automatically indexed until a moderator verifies the original source and its context. Editorially checked does not mean independently clinically reviewed, and no research headline should change someone's medication or care plan by itself.
What could improve in one, five and ten years?
By 2027 · near term
New trial readouts, evidence for medication mechanisms and wearable stimulation, and expanded use of existing treatments where justified. Approval and access dates remain uncertain.
By 2031 · medium term
Possible advances in individualizing medication selection and brain-stimulation protocols, alongside more usable digital supports. Larger, longer studies must confirm which approaches work.
By 2036 · longer term
Adaptive brain-circuit therapies and targeted treatments for some genetically defined conditions are plausible research directions, but not a forecast of universal cures.
These are research horizons—not guaranteed breakthroughs. For detailed condition-specific options, clinical limitations and source links, read the treatment and neurotechnology guide.
Follow research in four simple steps
STEP 1
Choose a condition or topic
Follow autism, ADHD, OCD, Tourette syndrome, schizophrenia, depression, anxiety, PTSD, bipolar disorder or emerging neurotechnology.
STEP 2
Read the source—not just the headline
Every automated listing identifies the source and cautions against interpreting recruitment or publication as proof of safety or effectiveness.
STEP 3
Save it for later
Save individual stories, use a calmer reading view and adjust the text size. Signed-in bookmarks can sync across devices.
STEP 4
Control research email preferences
Choose a weekly or monthly preference and explicitly opt in. Outbound research-digest sending is not yet enabled; the in-app feed remains available.
Research priorities when conditions overlap
For people with several diagnoses, the questions change. A medicine or device studied in one condition may not have been evaluated in people with psychosis, severe anxiety, tics, epilepsy or complex medication regimens. Ask about trial exclusions and whether the intervention could worsen another symptom.
- OCD: established ERP, indication-specific TMS and highly specialized stimulation research.
- Tourette syndrome: CBIT, wrist-stimulation studies and investigational medication options.
- Schizophrenia: approved medications and newer mechanisms alongside specialist treatment-resistant care.
- Autism and ADHD: supports matched to individual needs, careful treatment of co-occurring symptoms and emerging targeted research.
- Depression and anxiety: evidence-based therapies, appropriate medication and selected stimulation protocols; psychedelic studies require special attention to psychosis risk.
Compare new approaches and medical-tourism claims →
Questions readers ask
Can Neuralink treat schizophrenia, OCD or autism?
No demonstrated clinical benefit has been established for those conditions. Current implanted brain-computer interfaces focus primarily on communication or device control for severe motor disabilities.
Does Visible treat ADHD, anxiety, Tourette syndrome or schizophrenia?
Visible focuses on pacing and tracking fatigue and energy-limiting symptoms. It may help some people understand energy patterns, but is not an established treatment for those psychiatric or neurodevelopmental diagnoses.
Are overseas stem-cell or psychedelic clinics proven alternatives?
Availability in another country does not establish effectiveness. Evidence, regulation, study supervision, adverse effects and follow-up care need independent verification. Psychosis history requires particular caution with psychedelics.
Are my reading preferences or care notes sent to MailerLite?
Your selected topics and private Care Plan stay in NeuroCoach's protected account database. The proposed email digest links to a signed-in research feed rather than sharing individual medical notes or diagnostic interests with MailerLite.
When do research emails start?
The source-monitoring feed is operational. Automatic research emails remain disabled while verified sender credentials, an appropriate email plan, editorial review and consent checks are finalized.
Educational editorial guide · Updated October 2026. Source records and regulatory status may change. Confirm any clinical decisions with qualified clinicians familiar with the individual's full history. No individual treatment or device is endorsed solely because it appears in Research Watch.